Key Takeaways
- Record quarter, broad-based: Revenue grew 19% YoY to ₹698 crore and EBITDA grew 21% YoY to ₹87 crore, both all-time highs, with all three divisions contributing.
- Margins recovering but freight bites: Gross margin rebounded ~200 bps sequentially to 31.6% on better product mix, but freight costs that have doubled or tripled YoY are a material drag on EBITDA margin recovery.
- Export engine firing: Exports hit 31% of revenue in Q2, with HPPC export revenue up ~34% YoY and ~35% QoQ; the Thailand blending facility is starting to contribute and new geographies are opening.
- B2C breaks even, divestment still on: The institutional/B2C business turned EBITDA-positive (₹0.2 crore) after many quarters of losses, but management reiterated the plan to exit this non-core business at the right time and value.
- What to watch next quarter: Whether ethylene oxide supply constraints ease as guided, the pace of freight cost normalization, and any concrete Board-level details on the Saudi Arabia greenfield project.
Topline & Profitability
- Revenue composition: HPPC grew 18% YoY to ₹541.9 crore, led by value-added products in personal care, agro surfactants, adjuvants and oil and gas solutions; constrained ethylene oxide availability continued to limit ethoxylate volumes.
- Textile breakout: Textile revenue grew 26% YoY to ₹120.8 crore, with ~14% sequential growth, driven by export markets (Bangladesh, Southeast Asia, Turkey, Latin America), the Thailand facility, a new fiber chemical division, and a higher share of silicon-based and sustainable auxiliaries.
- AHN steady in low season: Animal Health & Nutrition grew 11% YoY to ₹34.8 crore despite Q2 being the seasonally weakest quarter; the vitamin premix plant, trace minerals, and enzyme and probiotic portfolio supported growth, with peak season expected in Q3 and Q4.
- Volume-led growth: Most of the Q2 growth was volume-driven as raw material prices softened in early Q2 and product prices were reduced accordingly.
- Gross margin walk: Gross margin at 31.6% was in line with Q2 FY26 and ~200 bps above Q1 FY27's 29.6%, driven by better product mix including tail cutting of the bottom 5% lowest-margin products and focus on higher-margin products in both export and domestic markets.
- Core B2B margin moderation: Core B2B EBITDA margin at 14.1% vs 14.8% in Q2 FY26, reflecting raw material and freight environment and ongoing investment in seeding new businesses and geographies.
- Balance sheet strengthening: Gross borrowings reduced by ~₹46 crore during H1 to ₹361.8 crore; net debt at ₹221 crore vs ₹248 crore in June and ₹281 crore in March; net debt-to-equity at 0.16; working capital days improved to 86 days from 97 days at FY26-end.
- Working capital improvement: The 10-day improvement in net working capital was driven by sustained efforts in rationalizing inventory and improving the collection cycle, not by customer priority in a raw-material-shortage scenario.
- Cash flow generation: H1 positive cash flow of ₹131 crore; net debt reduced from ₹280 crore to ₹220 crore; the BRPL business turned positive.
Ketan Sablok: "Even though our exports have grown significantly, the freight costs have almost doubled, tripled over what they were in the first half of last year or Q2 of last year. That has significantly impacted our EBITDA margins."
Export & International Expansion
- Export milestone: Exports contributed close to 31% of revenue in Q2, up from 27% in H1, driven by both HPPC and Textile segments; management targets at least 30%+ from exports by FY27-end.
- HPPC export surge: HPPC export revenue grew ~34% YoY and ~35% QoQ, with personal care as a key driver and oil and gas also seeing traction.
- Textile export geography play: Textile export revenue grew about 15% YoY, driven by seeding new geographies (Latin America, Southeast Asia, African countries) and the Thailand setup starting to play a role.
- Thailand facility ramp: The new blending facility in Thailand is ramping up steadily, helping serve Southeast Asian customers with customized formulations, faster turnaround times and lower exposure to freight volatility.
- Saudi Arabia greenfield: Board approved leasing of land to a wholly owned subsidiary for a greenfield manufacturing facility in KSA; initial activities like fencing and boundary wall expected in the next few months; the full project blueprint (financials, CAPEX, products, market sizing) is being worked on and will go back to the Board for approval, with some developments expected over the next 8 to 12 months.
New Initiatives & Product Pipeline
- Pharma surfactants: Received EXCiPACT registration for the Unitop plant, allowing pharma surfactants and excipients to be exported without customer audits, reducing audits and costs for both customers and the company; management is confident of very good growth in pharma this year.
- Aroma chemicals: Piloting is done and a higher-capacity setup is being built; still a couple of quarters away from significant contributions.
- Biosurfactants expansion: Good results seen from initial work, with further expansion planned.
- Hydrogenation: A new initiative under development.
- Margin trajectory from new lines: Once pharma and aroma chemicals become a significant part of the business, steady gross margin improvement should follow, given their higher-margin profile.
Sunil Chari: "So once you get it to the customer, the customer does not throw you out fast. Price and all are not the key criteria for changeover in a pharma kind of excipient."
Institutional & B2C Business
- Break-even achieved: The institutional and B2C business reported positive EBITDA of ₹0.2 crore in Q2 FY27 vs a loss of ₹3.7 crore in Q2 FY26, reflecting calibrated steps on portfolio rationalization, product mix and cost discipline.
- H2 and full-year outlook: Management aims for H2 FY27 to be EBITDA positive; on a full-year basis, the business should at least breakeven, given Q1 had a loss.
- Divestment intent unchanged: The overall plan remains to move out of the non-core B2C business; until then, the aim is to run it on a positive note.
Ketan Sablok: "We still are on that plan of moving out of this B2C business. We will do that, as we had said last time also, at an appropriate time and at an appropriate value. Till we reach that point, I think our aim is that we should still run this business on a positive note and that is what we are doing. But our overall plan still remains to move out of the non-core businesses that we have."
Raw Material & Supply Chain
- Ethylene oxide constraint: Constrained EO availability continued to limit ethoxylate volumes in Q2; management is hoping for no EO constraints in Q3 FY27.
- Reliance expansion timeline: Reliance EO expansion expected to kick in from Q1 of next financial year, with higher EO allocation expected from Q1; incremental quantity confirmation expected in the next couple of months, though no confirmation from Reliance on quantity yet.
- Dahej ethoxylation ramp: The new ethoxylation facility is expected to reach healthy utilization by Q2 or Q3 of next year, when Reliance capacities come in and EO flows increase; peak utilization expected by end of FY28, with peak sales revenue target of 3x CAPEX value.
- Raw material price pass-through: Prices of core raw materials like phenol have gone up significantly over last year; most increases are passed on but the freight element remains a challenge, as not all customers are ready to absorb the entire freight increase.
Capital Allocation & Balance Sheet
- Debt reduction first: First priority with cash flows is debt reduction; most CAPEX spend is done, with remaining spends this year not to the extent already done; future CAPEX in India is expected to be significantly low.
- KSA funding mix: The Saudi Arabia project will have an equity and debt mix; cash from operations and non-core asset sales will go first to debt reduction, then to the Saudi project depending on timelines.
- Working capital debt timeline: Working capital debts expected to be paid off by mid of next year, making the company debt-free on that portion; long-term borrowing trajectory depends on cash flows and could be paid off earlier.
- Net working capital target: Aim is to be in the 90-day range; at 87 days in September, management expects to remain within 87 to 90 days by end-March.
- ROCE trajectory: Expected to start improving once capacity utilizations of CAPEX spent in the last two years improve; upward trajectory likely next year, aided by working capital improvement and debt reduction.
- Most current CAPEX projects will close by the end of this year; no significant CAPEX spend expected over the next year, after which focus shifts to KSA.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Export revenue share | At least 30%+ of revenue from exports | By end of FY27 |
| Institutional/B2C profitability | H2 FY27 EBITDA positive; full-year at least breakeven | FY27 |
| FY27 revenue growth | Mid-teen to high-teen percentage (raised from initial 12–14%) | FY27 |
| FY27 EBITDA margin | Around 12% plus/minus for the full year | FY27 |
| EBITDA margin improvement | Improvements in EBITDA percentage expected | From next year (FY28) |
| Ethylene oxide supply | Hoping no EO constraints; Reliance expansion expected to bring higher allocation | Q3 FY27 (no constraint); Q1 FY28 (higher allocation) |
| Dahej ethoxylation utilization | Healthy utilization expected; peak utilization by end of FY28 | Q2–Q3 FY28 (healthy); FY28-end (peak) |
| Working capital debt | Paid off, debt-free on that portion | By mid of next year |
| Net working capital days | Remain within 87–90 days | By end-March FY27 |
| ROCE | Upward trajectory likely | Next year (FY28) |
| KSA project details | Blueprint, financials, CAPEX, products to be shared with Board | Some developments over next 8–12 months |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹697.6 cr, +19% YoY over ₹586.1 cr in Q2 FY26, highest-ever quarterly revenue |
| Gross margin | 31.6%, in line with Q2 FY26, +200 bps QoQ from 29.6% in Q1 FY27 |
| EBITDA | ₹87 cr, +21% YoY, highest-ever quarterly EBITDA |
| EBITDA margin | 12.5%, vs 12.3% in Q2 FY26 and 11.6% in Q1 FY27, +91 bps QoQ |
| Profit after tax | ₹38.9 cr, +5.5% YoY and +11% QoQ |
| Diluted EPS | ₹7.02 |
| Core B2B revenue | ₹619.9 cr, +21% YoY |
| Core B2B EBITDA margin | 14.1%, vs 14.8% in Q2 FY26 and 13.5% in Q1 FY27 |
| Institutional and B2C revenue | ₹77.7 cr, +3% YoY |
| Institutional and B2C EBITDA | ₹0.2 cr positive, vs EBITDA loss of ₹3.7 cr in Q2 FY26 |
| HPPC revenue | ₹541.9 cr, +18% YoY |
| Textile Speciality Chemicals revenue | ₹120.8 cr, +26% YoY, +~14% QoQ |
| Animal Health and Nutrition revenue | ₹34.8 cr, +11% YoY |
| Export contribution | ~31% of revenue, vs 27% in H1 FY27 |
| Net debt | ₹221 cr, vs ₹248 cr in Jun '26 and ₹281 cr in Mar '26 |
| Net debt-to-equity ratio | 0.16 |
| Working capital days | 86 days, improved from 97 days at end of FY26 |
| Blended capacity utilization | ~60% |
| New ethoxylation facility utilization | ~30%, ramping up |